secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001104659-23-056887
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Therapeutics Q1 net loss $52.8M; IGALMI formulary wins double to 130
----------------------------------------------------------------------------

- Net revenue ~$206K for Q1 2023; net loss of $52.8M vs $31.5M YoY.
- Cash $165.5M; cash runway into 2025 with Oaktree/QIA financing and IGALMI revenues.
- IGALMI: 130 formulary wins (doubled in 2 months); $55M market unlocked, $255M scheduled for vote.
- Key pipeline data expected: SERENITY III (May 2023), TRANQUILITY II (June 2023), MDD Phase 1b (May 2023).
- R&D expenses $27.8M (+49% YoY); SG&A $23.6M (+83% YoY) driven by IGALMI launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465923056887/0001104659-23-056887-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465923056887/tm239728d5_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-056887

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer